Primellose®

Croscarmellose Sodium

Primellose<sup>®</sup>
Croscarmellose Sodium Fast Water Uptake Allows Intra- Granular Or Extra- Granular

Specifications

Density Tapped density g/l
Bulk density g/l
Particle size D10
D50
D90
Hausner ratio

Production site

Foxhol, the Netherlands
  Conforms to USP-NF, Ph.Eur., JP

Quantity in kg

- +

Price per kg

$28.75

Size

Want to try first? Request your free sample here

Total

$1,006.25

Expected delivery within 5-7 days. Each order ships with Certificate of Analysis, Material Safety Data Sheet and Product Data Sheet.

Primellose® is DFE Pharma’s product brand name for Croscarmellose
Sodium. It is made in a dedicated pharmaceutical plant in Foxhol,
The Netherlands. Primellose® croscarmellose sodium is suitable for a
variety of tablet and capsule formulations. Primellose® is effective in
combination with both insoluble filler-binders and slightly soluble to
soluble filler-binders at concentrations of 2%w/w - 6%w/w. It is also a
choice for formulations which require non-starch products. Primellose®
is effective when used intragranular and/or extragranular in granular
formulations.

Fast delivery

Halal and kosher certificates

Best Pharmaceutical grade lactose

Small quantities

Additional information

Superior performance Primellose® can be used in wet granulation, dry granulation or direct compression in combination with nearly any type of API and excipient(s) (soluble or slightly soluble). Wicking is the most important factor in croscarmellose sodium performance, and it was found that the relatively large particle size distribution of Primellose® conferred superior performance compared to many other brands.

 

In wet granulation

We recommend that Primellose® is incorporated at least partly (50%w/w or more) during granulation. This is especially important when a high proportion of insoluble diluent is employed as shown in this example which uses Diclofenac Sodium as the API and dibasic calcium phosphate dihydrate as the main diluent.

 

In direct compression

The recommended starting point is 2%w/w to 6%w/w of Primellose®. Table 1 shows how the disintegration time of various placebo tablets (250 mg / 9 mm tablets containing 4%w/w Primellose® and 0.5%w/w magnesium stearate) is maintained after storage for 6 months at 40˚C / 75% RH in open containers. The disintegration of reference tablets stored for 6 months under ambient laboratory conditions is also shown. This data confirms that Primellose® remains an effective super-disintegrant, even under the most stressful stability storage conditions.

Document Overview

Because our PDF QAR documents are technically certified, you may experience difficulties when opening them in a browser. Save the PDF file first and then open the PDF file in a standard PDF reader (e.g. Adobe Reader)

On Off

Show all description

Technical papers

Show description

Show description

Show description

Product sheets

Show description

Brochure

Show description

Process flow sheets

Show description

Contaminants

Show description

GMO

Show description

Halal certificates

Show description

Kosher

Show description

Impurity statements

Show description

Ingredient Declaration

Show description

MSDS

Show description

Nutritional

Show description

Other quality and regulatory documents

Show description

Show description

Show description

Show description

Show description

Show description

Show description

Show description

Show description

Show description

Show description

Show description

Show description

Show description

Show description

Show description

Show description

Residual solvent

Show description

Shelf life

Show description

ALBA

Show description

Shopping Cart

×

Product title

1 x $29.95

Subtotal

Check Out